Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-20T11:42:20.089Z Has data issue: false hasContentIssue false
  • English
  • Français

The Economic Costs of Acute Myeloid Leukemia in Sweden

Published online by Cambridge University Press:  10 March 2009

Gunnel Ragnarson Tennvall ,
Ulf Persson  and
Bo Nilsson
Gunnel Ragnarson Tennvall
Affiliation:
The Swedish Institute for Health Economics (IHE)
Ulf Persson
Affiliation:
The Swedish Institute for Health Economics (IHE)
Bo Nilsson
Affiliation:
Pharmacia
Get access Rights & Permissions [Opens in a new window]

Abstract

The direct and indirect costs of acute myeloid leukemia were estimated for Sweden in 1989. The calculated total cost was SEK 460 million. Nearly half of the costs, or 1.7 million per patient diagnosed, were indirect costs due to premature mortality. Direct costs of relapses and indirect costs of mortality represent costs due to the absence of completely curable therapy. They also represent potential cost savings that could be ootained after introduction of new treatment options in the future.

Type
General Essays
Information
International Journal of Technology Assessment in Health Care , Volume 10 , Issue 4 , Fall 1994 , pp. 683 - 694
Copyright
Copyright © Cambridge University Press 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Bandini, G., Rosti, G., Calori, E. et al. , Long-term follow-up of patients who received an allogeneic marrow transplant (BMT) over 6 years at a single center. Proceedings of the 19th Annual Meeting of the European Bone Marrow Transplant Society. Garmisch-Partenkirchen, 01 17–23, 1993, 121.Google Scholar
2.Beard, M. E. J.Inder, A. B.Allen, J. R. et al. The costs and benefits of bone marrow transplantation. New Zealand Medical Journal, 1991, 104, 303–05.Google ScholarPubMed
3.Burnett, A. K.Use of autologous bone marrow transplantation in acute myeloid leukemia. Haematology and Blood Transfusion: Modern Trends in Human Leukaemia VII, 1987, 31, 62–66.CrossRefGoogle ScholarPubMed
4.Cassileth, P. A., Harrington, D. P., Hines, J. D. et al. , Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. Journal of Clinical Oncology, 1988, 6, 583–87.CrossRefGoogle ScholarPubMed
5.Drummond, M.Cost-of-illness studies a major headache? PharmacoEconomics, 1992, 2, 1–4.CrossRefGoogle ScholarPubMed
6.Drummond, M., Stoddard, G. L., & Torrance, G. W.Methods for the economic evaluation of health care programmes. Oxford, England: Oxford University Press, 1990.Google Scholar
7.Dufoir, T., Saux, M. C., Terraza, B. et al. , Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission. Bone Marrow Transplantation, 1992, 10, 323–29.Google ScholarPubMed
8.Foon, K. A., & Gale, R. P.Acute myelogenous leukemia: Current status of therapy in adults. Recent Results in Cancer Research, 1984, 93, 216–39.CrossRefGoogle ScholarPubMed
9.Gahrton, G., Ljungman, P., Ringdén, O., & Robért, K. H.Benmärgstransplantation (Bone marrow transplantation). Stockholm, Sweden: SBU, Statens Beredning för Utvärdering av medicinsk metodik (The Swedish Council on Technology Assessment in Health Care), 1991.Google Scholar
10.Greer, J. P., & Kinney, M. C. Acute nonlymphocytic leukemia. In Lee, G. R., Bithell, T. C., Foerster, J., et al. (eds.), Wintrobe's clinical hematology, Vol. 2. London: Lea & Febiger, 1993, 1920–45.Google Scholar
11.Hartunian, N. S., Smart, C. N., & Thompson, M. S.The incidence and economic costs of major health impairments. Lexington, MA: Lexington Books, 1981.Google Scholar
12.Jarvinen, D.Cost of illness studies. An annotated bibliography. San Francisco, CA: The Institute for Health and Aging, University of California, 1988.Google Scholar
13.Jones Lee, M. W.The economics of safety and physical risk. Oxford, England: Basil Blackwell, 1989.Google Scholar
14.Keskimaki, R. Returning to work after bone marrow transplantation. Proceedings of the 19th Annual Meeting of the European Bone Marrow Transplant Society. Garmisch-Partenkirchen, 01 17–23, 1993, 174.Google Scholar
15.Landstingsförbundet (The Federation of County Councils). Kostnaderper intagenpatient, vårddag, Iäkarbesök m m 1982. Stockholm, Sweden: Landstingsförbundet, 1984.Google Scholar
16.Landstingsförbundet (The Federation of County Councils). Kostnadsjämförelser mellan sjukhuskliniker 1985 med tillbakablickar. Stockholm, Sweden: Landstingsförbundet, 1987.Google Scholar
17.Landstingsforbundet (The Federation of County Councils). Kostnader per intagen patient, vårddag, Iäkarbesök m m 1988. Stockholm, Sweden: Landstingsförbundet, 1990.Google Scholar
18.Landstingsförbundet (The Federation of County Councils). Statistisk årsbok för landsting 1992/93. Stockholm, Sweden: Landstingsförbundet, 1992.Google Scholar
19.Lindgren, B.Costs of illness in Sweden 1964–1975. Lund, Sweden: Liber, 1981.Google Scholar
20.Lindgren, B. The cost of “non-treatment.” In Teeling-smith, (ed.), Measuring the benefits of medicines. The future agenda. London: Office of Health Economics, OHE, 1989.Google Scholar
21.Löwenberg, B., Verdonck, L J., Dekker, A. W. et al. , Autologous bone marrow transplantation in acute myeloid leukemia in first remission: Results of a Dutch prospective study. Journal of Clinical Oncology, 1990, 8, 287–94.CrossRefGoogle ScholarPubMed
22.The National Board of Health and Welfare. Stockholm, Sweden: Epidemiology Centre, 1989.Google Scholar
23.The National Board of Health and Welfare. Stockholm, Sweden: The Swedish Cancer Registry, 1992.Google Scholar
24.Persson, U.Three economic approaches to valuing benefits of traffic safety measures. Lund, Sweden: The Swedish Institute for Health Economics, IHE, 1992.Google Scholar
25.Persson, U., Ragnarson Tennvall, G., Andersson, S. et al. , Cost-effectiveness analysis of treatment with liposomal Amphotericin B versus conventional Amphotericin B in organ or bone marrow transplant recipients with systemic mycoses. PharmacoEconomics, 1992, 2, 500–08.CrossRefGoogle ScholarPubMed
26.Preisler, H. D., Davis, R. B., Kirshner, J. et al. , Comparison of three remission induction regimens and two post-induction strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leukemia Group B Study. Blood, 1987, 69, 1441–49.Google Scholar
27.Reiffers, J., Gaspard, M. H., Maraninchi, D. et al. , Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: A prospective controlled trial. British Journal of Haematology, 1989, 72, 57–63.CrossRefGoogle ScholarPubMed
28.Ringdén, O., Zwaan, F., Hermans, J., & Gratwohl, A.European experience of bone marrow transplantation for leukemia. Transplantation Proceedings, 1987, 14, 2600–04.Google Scholar
29.Rowe, J. M., Cassileth, P. A., Oken, M. M. et al. , Clinical trials in adults with acute myelogenous leukemia: The ECOG experience. In Gale, R. P. (ed.), Acute myelogenous leukemia: Progress and controversies. New York: Wiley-Liss, 1990, 293–309.Google Scholar
30.Schiffer, C. A., & Mayer, R. J. Cancer and Leukemia Group B studies in acute myeloid leukemia. In Gale, R. P. (ed.), Acute myelogenous leukemia: Progress and controversies. New York: Wiley-Liss, 1990, 313–22.Google Scholar
31.Shiell, A., Gerhard, K., & Donaldson, C.Cost of illness studies: An aid to decision making? Health Policy, 1987, 8, 317–23.CrossRefGoogle Scholar
32.Statistics Sweden. Causes of death 1989. Stockholm, Sweden: 1992.Google Scholar
33.Statistics Sweden. The income distribution survey 1989 (Be 21 SM 9101). Stockholm, Sweden: Statistics Sweden, 1991.Google Scholar
34.Statistics Sweden. Statistical yearbook of Sweden 1992. Stockholm, Sweden: Statistics Sweden, 1991.Google Scholar
35.Vaughan, W. P., Karp, J. E., & Burke, P. J.Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia. Blood, 1984, 64, 975–80.CrossRefGoogle ScholarPubMed
36.Welch, H. G., & Larson, E. B.Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. New England Journal of Medicine, 1989, 321, 807–12.CrossRefGoogle ScholarPubMed